**Name of journal:** *World Journal of Dermatology*

**ESPS Manuscript NO: 3906**

**Columns: EDITORIAL**

**Adipocytokines and psoriasis: Insights into mechanisms linking obesity and inflammation to psoriasis**

**Dalamaga M *et al*.** Adipocytokines and psoriasis

Maria Dalamaga, Evangelia Papadavid

**Maria Dalamaga,** Department of Clinical Biochemistry, Medical School, University of Athens, “Attikon” General University Hospital, Chaidari, 12462 Athens, Greece

**Evangelia Papadavid,** Department of Dermatology, Medical School, University of Athens, “Attikon” General University Hospital, Chaidari, 12462 Athens, Greece

**Author contributions:** Dalamaga M designed the editorial and wrote the manuscript; Papadavid E reviewed the manuscript.

**Correspondence to: Maria Dalamaga, MD, PhD, MS, MPH, Assistant Professor,** Department of Clinical Biochemistry, Medical School, University of Athens, “Attikon” General University Hospital, Karyotaki 29, 15344 Athens, Greece. madalamaga@med.uoa.gr

**Telephone:** +30-210-5831915 **Fax:** +30-210-6082467

**Received:** June 1, 2013  **Revised:** June 26, 2013

**Accepted:** July 4, 2013

 **Published online:**

**Abstract**

Psoriasis has been lately seen as a potential systemic inflammatory disease associated with a range of co-morbidities exhibiting an overlapping pathology and presenting a great social health impact such as cardiovascular disease and metabolic diseases, including obesity. Adipose tissue is considered a genuine endocrine organ producing a variety of bioactive adipocytokines, such as leptin, adiponectin, resistin and visfatin, participating in physiological and pathological processes, such as energy balance, insulin sensitivity and resistance, immunity, inflammation, hematopoiesis and angiogenesis. Adipocytokines could serve as a missing link in the association between psoriasis, obesity and metabolic co-morbidities. In chronic inflammatory disease states such as psoriasis, adipocytokines may be implicated in psoriasis onset, progression, severity as well as in the pathogenesis of co-morbidities. Measuring serum adipocytokine levels in the future may be useful in predicting psoriasis severity, progression, treatment outcome and risk of any co-morbidities. Interventions to decrease pro-inflammatory adipocytokine levels could offer preventive and therapeutic options for improving psoriasis severity and protecting against its co-morbidities. Candidate strategic interventions incorporate increased physical activity, weight control and pharmacologic approaches such as metformin. However, the mechanisms underlying the actions of adipocytokines in psoriasis as well as their potential diagnostic, prognostic and/or therapeutic utility require further investigation with larger prospective, longitudinal and mechanistic studies.

© 2013 Baishideng. All rights reserved.

**Key words:** Psoriasis; Adipocytokine; Obesity; Leptin; Adiponectin; Omentin; Resistin; Visfatin

**Core tip:** Adipocytokines could serve as a missing link in the association between psoriasis, obesity and metabolic co-morbidities. In chronic inflammatory disease states such as psoriasis, adipocytokines may be implicated in psoriasis onset, progression, severity as well as in the pathogenesis of co-morbidities. Measuring serum adipocytokine levels in the future may be useful in predicting psoriasis severity, progression, treatment outcome and risk of any co-morbidities. Interventions to decrease pro-inflammatory adipocytokine levels could offer preventive and therapeutic options for improving psoriasis severity and protecting against its co-morbidities. Candidate strategic interventions may incorporate increased physical activity, weight control and pharmacologic approaches such as metformin.

Dalamaga M, Papadavid E. Adipocytokines and psoriasis: Insights into mechanisms linking obesity and inflammation to psoriasis.

**PSORIASIS AND ADIPOSE TISSUE**

Psoriasis represents a complex, chronic, systemic, T-cell immune-mediated inflammatory dermatopathy characterized by skin and joint manifestations, and presenting commonly with erythematous, scaly plaques on various surfaces of the body[1,2]. Its prevalence varies approximately from 0.1% to 3% worldwide, with a mean prevalence rate of 1.90% in Western countries and a lower one in Asia[3].

The etiology of psoriasis remains unknown but the disease is believed to result from an interaction between genetic susceptibility and exogenous environmental factors, such as infection, in particular with β-hemolytic streptococci, stress and trauma[1-2,4]. Several human leukocyte antigen (HLA) alleles including HLA-Cw\*0602 are associated with psoriasis with *PSORS1* being the major susceptibility gene mapped next to the HLA-Cw6 antigen[2,5]. Moreover, non-HLA related genes and loci have been identified and associated with psoriasis risk such as interleukin (IL)-12B and IL-23R[2].

Psoriasis has been lately seen as a potential systemic inflammatory disease associated with a range of co-morbidities exhibiting an overlapping pathology and presenting a great social health impact such as cardiovascular disease, metabolic diseases, autoimmune disease, malignancy, chronic obstructive pulmonary disease, sleep apnea and psychiatric disorders[1,2,6,7]. Overweight/obesity, metabolic syndrome (Mets), diabetes mellitus type 2 (t2DM) and dyslipidemia occur at a higher frequency in psoriasis patients than in general population[8]. Mets constitutes a constellation of cardiometabolic risk factors comprising central obesity, impaired glucose tolerance, elevated blood pressure and dyslipidemia[9]. Both psoriasis and Mets share common genetic predisposition; though their exact interplay remains enigmatic. Also, psoriasis and metabolic disorders share common risk factors such as smoking, obesity, physical inactivity and psychological stress[8]. Hence, all these cardio-metabolic risk factors, lifestyle parameters and the underlying chronic systemic psoriatic inflammation may all contribute to an increased risk for cardiovascular disease.

Apart from its fat storage function, adipose tissue constitutes an active endocrine organ secreting several bioactive adipocytokines regulating physiological and pathological processes, such as appetite, insulin sensitivity and resistance, immunity, inflammation, hematopoiesis and angiogenesis[10]. Increased adiposity following weight gain is associated with elevated levels of adipocytokines, comprising leptin, resistin and visfatin, and decreased levels of adiponectin and omentin, that may promote stimulation of monocytes and T cells, leading to both T-helper (Th)1 and Th17 immune responses and impairing the function of T regulatory cells[10-12]. Besides, the etiopathogenesis of Mets is attributed to hyperinsulinemia and insulin resistance mediated by adipocytokines, such as TNF-α, leptin, adiponectin and resistin[11]. It seems that obesity may potentiate the inflammation of psoriasis while, at the same time, it may help the development of Mets. Therefore, adipocytokines may represent a missing link in the association between psoriasis and metabolic co-morbidities, and could be used as potential biomarkers for assessing psoriasis severity, progression, treatment outcome, and risk of co-morbidities.

**ADIPOCYTOKINES AND PSORIASIS**

***Leptin***

Leptin is a 16-kDa, 167-amino acid adipocytokine that is primarily produced in adipose tissue. It is a pleiotropic molecule regulating food intake, appetite, energy expenditure, immunity, inflammation, hematopoiesis, cell differentiation and proliferation[12,13]. Leptin levels are directly proportional to the amount of body fat and fluctuate with acute changes in caloric intake, signaling the amount of energy stored in adipose tissue[12,13]. Although patients with hypoleptinemia and leptin deficiency are obese, common forms of obesity, insulin resistance and metabolic syndrome are accompanied by hyperleptinemia due to leptin resistance[12]. Leptin may be involved in the pathogenesis of psoriasis. It stimulates monocytes and macrophages, enhances the secretion of proinflammatory cytokines tumor necrosis factor-alpha (TNF-α), IL-6, IL-1, and IL-12, and shifts T-cell differentiation to Th1 phenotype[12,14]. Leptin stimulates also keratinocyte proliferation, angiogenesis and expression of adhesion molecules[14]. Despite the small size of epidemiologic studies and the lack of adjustment for body mass index (BMI) in analyses, the majority of studies examining the association between leptin and psoriasis has documented that psoriasis is associated with hyperleptinemia[14-17]. Also, elevated leptin levels characterize psoriatic arthritis and correlate with Psoriatic Arthritis Joint Activity Index[18]. In most studies, leptin correlated with Psoriasis Area Severity Index (PASI) score, representing, therefore, a biomarker of psoriasis severity and chronicity[19]. Indeed, severely affected psoriatic patients exhibit a significant increase in leptin levels compared to moderately affected patients[14]. Furthermore, leptin receptor and leptin expression in skin biopsies were found increased in severe psoriasis[19]. However, a possible association of psoriasis with leptin needs to be analyzed further with larger prospective, longitudinal and mechanistic studies in order to provide further insights into the paracrine and endocrine mechanisms underlying leptin’s role in psoriasis.

***Adiponectin and omentin***

Adiponectin is a 30-kDa, 244-amino-acid protein produced predominantly by white adipose tissue, sharing a homology with TNF-α, collagen VIII, X and complement factor C1q[10,11]. Adiponectin exhibits insulin-sensitizing, anti-inflammatory, anti-atherogenic, cardioprotective and anti-neoplastic effects as well as distinct actions in lipid metabolism[10,11]. The high molecular weight isoform is the biologically active configuration of adiponectin, being related with Mets, insulin resistance and cardiovascular disease[11]. Hypoadiponectinemia is the common pathodenominator of the constellation of risk factors that compose Mets, such as hypertension, dyslipidemia, obesity, hyperglycemia and insulin resistance[11]. In contrast, hyperadiponectinemia is present in chronic inflammatory and autoimmune diseases not related to obesity such as rheumatoid arthritis and inflammatory bowel disease[10]. Adiponectin exhibits powerful anti-inflammatory properties by inhibiting the inflammatory cytokine network and down-regulating TNF-α-induced expression of endothelial adhesion molecules, TNF-α-expression in macrophages and adipose tissue, TNF-α-induced secretion of IL-6 in monocyte cells and keratinocytes *in vitro* as well as TNF-α, IL-6, IL-17, IL-22 and interferon-γ from T-lymphocytes[3,10,14]. Despite the fact that psoriasis is often associated with disease states characterized by hypoadiponectinemia such as Mets and obesity, controversial data exist in the literature regarding the association of adiponectinemia with psoriasis. A decrease, no change and even an increase in adiponectin levels have been reported in psoriasis patients[14,20-22]. Although not all results were adjusted for BMI, some studies have indicated a BMI independent change in adiponectin levels especially after treatment[21] as well as a negative correlation with PASI and pro-inflammatory cytokines such as TNF-α and IL-6[20,22].

Omentin, a newer 40-kDa adipocytokine, secreted mainly by stromal cells in the visceral fat, with similar properties to adiponectin, was found decreased in psoriatic patients in comparison to controls[23].

***Resistin***

Resistin is a 12 kDa cysteine-rich polypeptide which is produced in humans predominantly by stromal macrophages and monocytes of the visceral adipose tissue[24]. Elevated resistin levels are found in obesity and inflammation, and may play a significant role in the pathogenesis of insulin resistance, Mets and t2DM[24-27]. More importantly, resistin acts as a pro-inflammatory factor leading to an increased mRNA expression of twenty chemokines and cytokines including TNF-á, IL-1, IL-6, IL-12, chemokine ligand CXCL8, monocyte chemoattractant protein-1 and resistin itself via the nuclear factor-êÂ (ÍF-êB)[25]. In the majority of studies exploring the association of resistin with psoriasis, hyperrestinemia characterized untreated psoriatic patients and correlated with disease severity and nail psoriasis severity index [14,25-29].

***Visfatin and other adipocytokines***

Visfatin is a 52-kDa pleiotropic adipocytokine secreted by the macrophages of the visceral fat, acting as a cytokine, a growth factor and an enzyme, and playing a significant role in the cellular energy metabolism and in a variety of metabolic and stress responses[30-32]. Despite the conflicting association of visfatin with metabolic and anthropometric parameters, its concentrations are usually elevated in obese individuals, obese children and adolescents, in patients with coronary heart disease, t2DM, Mets and non-alcoholic fatty liver disease as well as in chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease[31-34]. Visfatin enhances the production of IL-1α, ΙL-6, TNF-α, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 through the pro-inflammatory transcription factor NF-κB, and may contribute to the pathogenesis of vascular inflammation of obesity[31,32]. Visfatin may play a significant role in psoriasis pathophysiology. In a small size study, serum visfatin was significantly elevated in psoriasis patients than in healthy controls, correlating positively with disease chronicity and severity[23]. *In vivo*, the visfatin gene expression profile was increased in proriasis while *in vitro* visfatinupregulated TNF-α-induced chemokine ligands: CXCL 8, 10 and CCL20 production and mRNA expression in human keratinocytes[35,36].

Data regarding newer and promising adipocytokines, such as vaspin, retinol-binding protein 4 and chemerin with respect to psoriasis are sparse and controversial [14,37].

The controversy of results in epidemiologic studies examining the association of adipocytokines with psoriasis may be attributed to the (1) retrospective study design; (2) small sample size; (3) non-adjustment of the results for BMI, waist circumference and metabolic parameters as well as for important confounders such as coronary disease; (4) different ethnic groups examined; (5) importance of measuring fasting samples versus non-fasting; and (6) different laboratory assays used.

In conclusion, adipocytokines such as leptin, adiponectin, resistin and visfatin represent key players in many physiologic processes including energy balance, immunity and inflammation. Adipocytokines could serve as a missing link in the association between psoriasis, obesity and metabolic co-morbidities. In chronic inflammatory disease states such as psoriasis, adipocytokines may be implicated in psoriasis onset, progression as well as in the pathogenesis of co-morbidities. Measuring serum adipocytokine levels in the future may be useful in predicting psoriasis severity, treatment success and risk of any co-morbidities. We also speculate that interventions to decrease pro-inflammatory adipocytokine levels could represent a preventive and therapeutic option for improving disease severity and protecting against its co-morbidities. Candidate strategic interventions incorporate increased physical activity[38], weight control and pharmacologic approaches such as metformin[10,11]. However, the mechanisms underlying the actions of adipocytokines in psoriasis as well as their potential diagnostic, prognostic and/or therapeutic utility require further investigation with larger prospective, longitudinal and mechanistic studies.

**REFERENCES**

1 **Nestle FO**, Kaplan DH, Barker J. Psoriasis. *N Engl J Med* 2009; **361**: 496-509 [PMID: 19641206 DOI: 10.1056/NEJMra0804595]

2 **Reich K**. The concept of psoriasis as a systemic inflammation: implications for disease management. *J Eur Acad Dermatol Venereol* 2012; **26** Suppl 2: 3-11 [PMID: 22356630 DOI: 10.1111/j.1468-3083.2011.04410.x]

3 **Chu TW**, Tsai TF. Psoriasis and cardiovascular comorbidities with emphasis in Asia. *G Ital Dermatol Venereol* 2012; **147**: 189-202 [PMID: 22481582]

4 **Telfer NR**, Chalmers RJ, Whale K, Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. *Arch Dermatol* 1992; **128**: 39-42 [PMID: 1739285]

5 **Griffiths CE**, Barker JN. Pathogenesis and clinical features of psoriasis. *Lancet* 2007; **370**: 263-271 [PMID: 17658397]

6 **Papadavid E**, Vlami K, Dalamaga M, Giatrakou S, Theodoropoulos K, Gyftopoulos S, Stavrianeas N, Papiris S, Rigopoulos D. Sleep apnea as a comorbidity in obese psoriasis patients: a cross-sectional study. Do psoriasis characteristics and metabolic parameters play a role? *J Eur Acad Dermatol Venereol* 2013; **27**: 820-826 [PMID: 22620285 DOI: 10.1111/j.1468-3083.2012.04580.x]

7 **Dalamaga M**, Papadavid E, Vlami K. Unmasking the Janus face of the association between psoriasis, metabolic syndrome and obstructive sleep apnea. *Sleep Breath* 2013; **17**: 449-450 [PMID: 22821224 DOI: 10.1007/s11325-012-0749-4]

8 **Takahashi H**, Iizuka H. Psoriasis and metabolic syndrome. *J Dermatol* 2012; **39**: 212-218 [PMID: 22035413 DOI: 10.1111/j.1346-8138.2011.01408.x]

9 **Doyle SL**, Donohoe CL, Lysaght J, Reynolds JV. Visceral obesity, metabolic syndrome, insulin resistance and cancer. *Proc Nutr Soc* 2012; **71**: 181-189 [PMID: 22051112 DOI: 10.1017/S002966511100320X]

10 **Dalamaga M**, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. *Endocr Rev* 2012; **33**: 547-594 [PMID: 22547160 DOI: 10.1210/er.2011-1015]

11 **Ziemke F**, Mantzoros CS. Adiponectin in insulin resistance: lessons from translational research. *Am J Clin Nutr* 2010; **91**: 258S-261S [PMID: 19906806 DOI: 10.3945/ajcn.2009.28449C]

12 **Moon HS**, Dalamaga M, Kim SY, Polyzos SA, Hamnvik OP, Magkos F, Paruthi J, Mantzoros CS. Leptin's Role in Lipodystrophic and Nonlipodystrophic Insulin-Resistant and Diabetic Individuals. *Endocr Rev* 2013; **34**: 377-412 [PMID: 23475416 DOI: 10.1210/er.2012-1053]

13 **Dalamaga M**, Chou SH, Papageorgiou P, Shields K, Polyzos SA, Mantzoros CS. Leptin at the Intersection of Neuroendocrinology and Metabolism: Current Evidence and Therapeutic Perspectives. *Cell Metab* 2013; : [PMID: 23770129]

14 **Gerdes S**, Rostami-Yazdi M, Mrowietz U. Adipokines and psoriasis. *Exp Dermatol* 2011; **20**: 81-87 [PMID: 21255085 DOI: 10.1111/j.1600-0625.2010.01210.x]

15 **Wang Y**, Chen J, Zhao Y, Geng L, Song F, Chen HD. Psoriasis is associated with increased levels of serum leptin. *Br J Dermatol* 2008; **158**: 1134-1135 [PMID: 18294316]

16 **Chen YJ**, Wu CY, Shen JL, Chu SY, Chen CK, Chang YT, Chen CM. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. *Arch Dermatol* 2008; **144**: 1571-1575 [PMID: 19075139 DOI: 10.1111/j.1365-2133.2008.08456.x]

17 **Takahashi H**, Tsuji H, Takahashi I, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. *Br J Dermatol* 2008; **159**: 1207-1208 [PMID: 18795929 DOI: 10.1111/j.1365-2133.2008.08823.x]

18 **Xue Y**, Jiang L, Cheng Q, Chen H, Yu Y, Lin Y, Yang X, Kong N, Zhu X, Xu X, Wan W, Zou H. Adipokines in psoriatic arthritis patients: the correlations with osteoclast precursors and bone erosions. *PLoS One* 2012; **7**: e46740 [PMID: 23144698 DOI: 10.1371/journal.pone.0046740]

19 **Cerman AA**, Bozkurt S, Sav A, Tulunay A, Elbaşi MO, Ergun T. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. *Br J Dermatol* 2008; **159**: 820-826 [PMID: 18637894 DOI: 10.1111/j.1365-2133.2008.08742.x]

20 **Gerdes S**, Osadtschy S, Rostami-Yazdi M, Buhles N, Weichenthal M, Mrowietz U. Leptin, adiponectin, visfatin and retinol-binding protein-4 - mediators of comorbidities in patients with psoriasis? *Exp Dermatol* 2012; **21**: 43-47 [PMID: 22151390 DOI: 10.1111/j.1600-0625.2011.01402.x]

21 **Shibata S**, Tada Y, Hau C, Tatsuta A, Yamamoto M, Kamata M, Karakawa M, Asano Y, Mitsui H, Sugaya M, Kadono T, Saeki H, Kanda N, Sato S. Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis: induction of elevated serum adiponectin levels following therapy. *Br J Dermatol* 2011; **164**: 667-670 [PMID: 21062267 DOI: 10.1111/j.1365-2133.2010.10123.x]

22 **Shibata S**, Saeki H, Tada Y, Karakawa M, Komine M, Tamaki K. Serum high molecular weight adiponectin levels are decreased in psoriasis patients. *J Dermatol Sci* 2009; **55**: 62-63 [PMID: 19395243 DOI: 10.1016/j.jdermsci.2009.02.009]

23 **Ismail SA**, Mohamed SA. Serum levels of visfatin and omentin-1 in patients with psoriasis and their relation to disease severity. *Br J Dermatol* 2012; **167**: 436-439 [PMID: 22486212 DOI: 10.1111/j.1365-2133.2012.10980.x]

24 **Schwartz DR**, Lazar MA. Human resistin: found in translation from mouse to man. *Trends Endocrinol Metab* 2011; **22**: 259-265 [PMID: 21497511 DOI: 10.1016/j.tem.2011.03.005]

25 **Filková M**, Haluzík M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: Implications for various human pathologies. *Clin Immunol* 2009; **133**: 157-170 [PMID: 19740705 DOI: 10.1016/j.clim.2009.07.013]

26 **Dalamaga M**, Sotiropoulos G, Karmaniolas K, Pelekanos N, Papadavid E, Lekka A. Serum resistin: a biomarker of breast cancer in postmenopausal women? Association with clinicopathological characteristics, tumor markers, inflammatory and metabolic parameters. *Clin Biochem* 2013; **46**: 584-590 [PMID: 23321342 DOI: 10.1016/j.clinbiochem.2013.01.001]

27 **Dalamaga M**, Karmaniolas K, Papadavid E, Pelekanos N, Sotiropoulos G, Lekka A. Hyperresistinemia is associated with postmenopausal breast cancer. *Menopause* 2013; [Epub ahead of print] [PMID: 23481121]

28 **Coimbra S**, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A, Figueiredo A, Teixeira F, Castro E, Rocha-Pereira P, Santos-Silva A. Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. *J Eur Acad Dermatol Venereol* 2010; **24**: 1386-1394 [PMID: 20337818 DOI: 10.1111/j.1468-3083.2010.03647.x]

29 **Ozdemir M**, Yüksel M, Gökbel H, Okudan N, Mevlitoğlu I. Serum leptin, adiponectin, resistin and ghrelin levels in psoriatic patients treated with cyclosporin. *J Dermatol* 2012; **39**: 443-448 [PMID: 22300284 DOI: 10.1111/j.1346-8138.2011.01497.x]

30 **Dalamaga M**. Nicotinamide phosphoribosyl-transferase/visfatin: a missing link between overweight/obesity and postmenopausal breast cancer? Potential preventive and therapeutic perspectives and challenges. *Med Hypotheses* 2012; **79**: 617-621 [PMID: 22922056 DOI: 10.1016/j.mehy.2012.07.036]

31 **Garten A**, Petzold S, Körner A, Imai S, Kiess W. Nampt: linking NAD biology, metabolism and cancer. *Trends Endocrinol Metab* 2009; **20**: 130-138 [PMID: 19109034 DOI: 10.1016/j.tem.2008.10.004]

32 **Zhang LQ**, Heruth DP, Ye SQ.Nicotinamide Phosphoribosyltransferase in Human Diseases. *J Bioanal Biomed* 2011; **3**: 13-25 [PMID: 22140607]

33 **Dalamaga M**, Karmaniolas K, Papadavid E, Pelekanos N, Sotiropoulos G, Lekka A. Elevated serum visfatin/nicotinamide phosphoribosyl-transferase levels are associated with risk of postmenopausal breast cancer independently from adiponectin, leptin, and anthropometric and metabolic parameters. *Menopause* 2011; **18**: 1198-1204 [PMID: 21712732 DOI: 10.1097/gme.0b013e31821e21f5]

34 **Dalamaga M**, Archondakis S, Sotiropoulos G, Karmaniolas K, Pelekanos N, Papadavid E, Lekka A. Could serum visfatin be a potential biomarker for postmenopausal breast cancer? *Maturitas* 2012; **71**: 301-308 [PMID: 22261365 DOI: 10.1016/j.maturitas.2011.12.013]

35 **Koczan D**, Guthke R, Thiesen HJ, Ibrahim SM, Kundt G, Krentz H, Gross G, Kunz M. Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules. *Eur J Dermatol* 2005; **15**: 251-257 [PMID: 16048752]

36 **Kanda N**, Hau CS, Tada Y, Tatsuta A, Sato S, Watanabe S. Visfatin enhances CXCL8, CXCL10, and CCL20 production in human keratinocytes. *Endocrinology* 2011; **152**: 3155-3164 [PMID: 21673103 DOI: 10.1210/en.2010-1481]

37 **Saalbach A**, Vester K, Rall K, Tremel J, Anderegg U, Beck-Sickinger AG, Blüher M, Simon JC. Vaspin--a link of obesity and psoriasis? *Exp Dermatol* 2012; **21**: 309-312 [PMID: 22417310 DOI: 10.1111/j.1600-0625.2012.01460.x]

38 **Wilson PB**, Bohjanen KA, Ingraham SJ, Leon AS. Psoriasis and physical activity: a review. *J Eur Acad Dermatol Venereol* 2012; **26**: 1345-1353 [PMID: 22385402 DOI: 10.1111/j.1468-3083.2012.04494.x]

 **P-Reviewers** Ayroldi E, Di Lernia DV **S-Editor** Gou SX  **L-Editor E-Editor**